1 王璇, 黄绍辉, 於丽乔, 等.DEK原癌基因与口腔鳞状细胞癌的关系[J].上海口腔医学, 2014, 23(1):75-79. 2 赵倩妤, 孙轶华.拉曼光谱在癌症组织学诊断中的研究进展[J].实用肿瘤学杂志, 2018, 32(1):92-96. 3 Mandú ALC, Lira CRSD, Silva LPD, et al.Study of immunohistochemical expression of mdm2 and bax proteins in oral squamous cell carcinoma[J].Oral Surg Oral Med O, 2015, 120(2):88-89. 4 Ayroldi E, Petrillo MG, Bastianelli A, et al.L-GILZ binds p53 and MDM2 and suppresses tumor growth through p53 activation in human cancer cells[J].Cell Death Differ, 2015, 22(1):118-130. 5 Loeffelbein D, Ritschl LM, Gull FD, et al.Influence of possible predictor variables on the outcome of primary oral squamous cell carcinoma:a retrospective study of 392 consecutive cases at a single centre[J].Int J Oral Maxillofac Surg, 2017, 46(4):413-421. 6 Zehnder AM, Swift LA, Sundaram A, et al.Clinical features, treatment, and outcomes of cutaneous and oral squamous cell carcinoma in avian species[J].J Am Vet Med Assoc, 2018, 252(3):309-315. 7 戚晓峰.Metformin增强口腔鳞癌对顺铂化疗敏感性的实验研究[D].南京:南京大学, 2017. 8 Ghosh RD, Ghuwalewala S, Das P, et al.MicroRNA profiling of cisplatin-resistant oralsquamous cell carcinoma cell lines enriched with cancer-stem-cell-like and epithelial-mesenchymal transition-type features[J].Sci Rep, 2016, 6:23932. 9 Qi M, Zhang J, Zeng W, et al.DNAJB1 stabilizes MDM2 and contributes to cancer cell proliferation in a p53-dependent manner[J].Biochimica Et Biophysica Acta, 2014, 1839(1):62-69. 10 Agarwal S, Mathur M, Srivastava A, et al.MDM2/p53 co-expression in oral premalignant and malignant lesions:potential prognostic implications[J].Oral Oncol, 1999, 35(2):209-216. 11 Li Q, Zhang Y, Elnaggar AK, et al.Therapeutic efficacy of p53 restoration in mdm2-overexpressing tumors[J].Molecular Cancer Research Mcr, 2014, 12(6):901-911. 12 Burgess A, Chia KM, Haupt S, et al.Clinical overview of MDM2/X-targeted therapies[J].Front Oncol, 2016, 6:7. 13 赵小美.TP53基因改变影响MDM2抑制剂对神经胶质瘤的效应及机制研究[D].河南:河南大学, 2011. 14 Shinohara T, Uesugi M.In-vivo activation of the p53 pathway by small-molecule antagonists of MDM2[J].Tanpakushitsu Kakusan Koso, 2007, 52(13 Suppl):1816-1817. 15 White MJ, Mcarthur K, Metcalf D, et al.The apoptotic caspase cascade suppresses mitochodrial DNA-induced STING-mediated type I IFN production by dying cells[J].Cell, 2014, 159(7):1549-1562. 16 詹平, 于小龙, 张斌, 等.CDK抑制剂NSC649890联合顺铂对人骨肉瘤细胞U2-OS的抑制作用[J].中国矫形外科杂志, 2017, 25(1):73-78. 17 Yu F, Yu C, Chen J, et al.Tetrandrine induces apoptosis via caspase-8, -9, and-3 and poly(ADP ribose)polymerase dependent pathways and autophagy through beclin-1/LC3-I, II signaling pathways in human oral cancer HSC-3 cells[J].Environmental Toxicology, 2016, 31(4):395-406. 18 周亮.MDM2和p21~(WAF1)在人脑胶质瘤中的表达及相关性分析[D].郑州:郑州大学, 2010. 19 胡纯琦.p53-MDM2结合抑制剂的设计、合成及生物学活性评价[D].浙江:浙江大学, 2012. 20 Zheng T, Yin D, Lu Z, et al.Nutlin-3 overcomes arsenic trioxide resistance and tumormetastasis mediated by mutant p53 in hepatocellular carcinoma[J].Molecular Cancer, 2014, 13(1):133. 21 Wu Q, Wang X, Liu J, et al.Nutlin-3 reverses the epithelial-mesenchymal transition in gemcitabine-resistant hepatocellular carcinoma cells[J].Oncology Reports, 2016, 36(3):1325-1332. 22 Jin L, Tabe Y, Kojima K, et al.MDM2 antagonist Nutlin-3 enhances bortezomib-mediated mitochondrial apoptosis in TP53-mutated mantle cell lymphoma[J].Cancer Lett, 2010, 299(2):161-170. 23 Hu L, Zhang H, Bergholz J, et al.MDM2/MDMX:Master negative regulators for p53 and RB[J].Mol Cellular Oncology, 2016, 3(2):1106635. |